ATE471328T1 - Verbindungen mit immunologischem adjuvanseffekt - Google Patents

Verbindungen mit immunologischem adjuvanseffekt

Info

Publication number
ATE471328T1
ATE471328T1 AT04009656T AT04009656T ATE471328T1 AT E471328 T1 ATE471328 T1 AT E471328T1 AT 04009656 T AT04009656 T AT 04009656T AT 04009656 T AT04009656 T AT 04009656T AT E471328 T1 ATE471328 T1 AT E471328T1
Authority
AT
Austria
Prior art keywords
compounds
novel
adjuvant effect
immunological adjuvant
adjuvant
Prior art date
Application number
AT04009656T
Other languages
English (en)
Inventor
Lynn D Hawkins
Sally T Ishizaka
Michael Lewis
Pamela Mcguinness
Anneliese Nault
Jeffrey Rose
Daniel P Rossignol
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE471328T1 publication Critical patent/ATE471328T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04009656T 1999-02-01 2000-02-01 Verbindungen mit immunologischem adjuvanseffekt ATE471328T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11813199P 1999-02-01 1999-02-01

Publications (1)

Publication Number Publication Date
ATE471328T1 true ATE471328T1 (de) 2010-07-15

Family

ID=22376670

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04009656T ATE471328T1 (de) 1999-02-01 2000-02-01 Verbindungen mit immunologischem adjuvanseffekt
AT00907124T ATE269341T1 (de) 1999-02-01 2000-02-01 Verbindungen mit immunologischem adjuvanseffekt

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00907124T ATE269341T1 (de) 1999-02-01 2000-02-01 Verbindungen mit immunologischem adjuvanseffekt

Country Status (21)

Country Link
US (1) US6290973B1 (de)
EP (2) EP1439184B1 (de)
JP (1) JP4698027B2 (de)
KR (1) KR100711561B1 (de)
AT (2) ATE471328T1 (de)
AU (2) AU768574B2 (de)
BR (1) BRPI0007936B8 (de)
CA (1) CA2361582C (de)
DE (2) DE60044570D1 (de)
DK (1) DK1147117T3 (de)
ES (2) ES2223464T3 (de)
FI (1) FI120689B (de)
HK (1) HK1043132B (de)
HU (1) HU226869B1 (de)
IL (3) IL144671A0 (de)
MX (1) MXPA01007760A (de)
NO (1) NO329111B1 (de)
NZ (1) NZ513259A (de)
PT (1) PT1147117E (de)
WO (1) WO2000044758A1 (de)
ZA (1) ZA200106487B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US7915238B2 (en) 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
YU72201A (sh) * 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
AU2001284354A1 (en) * 2000-07-31 2002-02-13 Eisai Co. Ltd. Immunological adjuvant compounds, compositions, and methods of use thereof
SI21352A (sl) 2001-01-23 2004-06-30 Aventis Pasteur Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
ES2314087T3 (es) * 2001-03-08 2009-03-16 The Trustees Of The University Of Pennsylvania Polimeros facialmente anfifilicos como agentes antiinfecciosos.
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
JP2006518701A (ja) * 2002-05-24 2006-08-17 ネオファーム、インコーポレイティッド カルジオリピン組成物、その製造方法及び使用
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
JP3900343B2 (ja) * 2002-09-05 2007-04-04 株式会社トリケミカル研究所 （ｒｏ）（ｒ’ｏ）（ｒ’’ｏ）ｍ＝ｏの製造方法
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
EP2263687B1 (de) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogene zusammensetzungen enthaltend phospholipid
WO2004082634A2 (en) * 2003-03-17 2004-09-30 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
US7202234B2 (en) * 2003-10-24 2007-04-10 Eisai Co., Ltd. Compounds and methods for treating Toll-like receptor 2-related diseases and conditions
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
JP5260877B2 (ja) * 2004-01-23 2013-08-14 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 面に対して両親媒性のポリアリール及びポリアリールアルキニルのポリマー及びオリゴマー並びにそれらの使用
CA2599205A1 (en) * 2005-02-25 2006-09-08 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CN103285392A (zh) 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
CA2611721C (en) 2005-06-30 2014-04-22 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
EP3067048B1 (de) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Zusammensetzungen zur induzierung von immunreaktionen
JP5399410B2 (ja) * 2007-12-18 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 免疫アジュバントｅ６０２０への合成前駆体のベータ−ケトアミド合成のための試薬および方法
KR101507822B1 (ko) 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
WO2013043580A2 (en) 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
US20150133551A1 (en) * 2012-05-03 2015-05-14 Beth Israel Deaconess Medical Center, Inc. Lipids That Increase Insulin Sensitivity And Methods Of Using The Same
EP2972399B1 (de) 2013-03-15 2020-09-02 Beth Israel Deaconess Medical Center, Inc. Lipide zur erhöhung der insulinempfindlichkeit und verfahren zur verwendung davon
EP3604271A1 (de) 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptide für aminosäure- und peptidkonjugate und konjugationsverfahren
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
WO2017214527A1 (en) 2016-06-10 2017-12-14 Beth Israel Deaconess Medical Center, Inc. Fatty acid esters of hydroxy fatty acids (fahfas) for use in the treatment of type 1 diabetes
NL2030835B1 (en) 2020-01-24 2022-12-29 Aim Immunotech Inc Methods, compositions, and vaccinces for treating a virus infection
CN113307824B (zh) 2021-04-26 2022-05-27 浙江大学 一种双亲性材料及其在制备脂质体中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2583892A (en) * 1991-09-11 1993-04-05 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JP3814290B2 (ja) * 1993-12-09 2006-08-23 エスクナー，ハインリッヒ 抗原用のアジュバントおよびその製法ならびに用途
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof

Also Published As

Publication number Publication date
HK1043132B (en) 2005-04-01
ZA200106487B (en) 2002-08-07
US6290973B1 (en) 2001-09-18
HK1043132A1 (en) 2002-09-06
AU2004201147A1 (en) 2004-04-22
PT1147117E (pt) 2004-10-29
EP1439184B1 (de) 2010-06-16
WO2000044758A1 (en) 2000-08-03
JP2002535411A (ja) 2002-10-22
EP1147117B1 (de) 2004-06-16
KR100711561B1 (ko) 2007-04-27
NO20013749D0 (no) 2001-07-31
AU2004201147B2 (en) 2008-04-03
IL174413A0 (en) 2009-02-11
HUP0105473A2 (hu) 2002-04-29
IL144671A0 (en) 2002-05-23
CA2361582C (en) 2010-04-06
DE60011571T2 (de) 2005-08-18
EP1439184A1 (de) 2004-07-21
HUP0105473A3 (en) 2003-11-28
NO329111B1 (no) 2010-08-30
BRPI0007936B8 (pt) 2021-05-25
DE60044570D1 (de) 2010-07-29
FI20011593L (fi) 2001-07-31
KR20010101912A (ko) 2001-11-15
BR0007936A (pt) 2002-04-09
DK1147117T3 (da) 2004-10-25
NZ513259A (en) 2004-05-28
IL144671A (en) 2006-07-05
HU226869B1 (en) 2010-01-28
AU2867500A (en) 2000-08-18
HK1070372A1 (en) 2005-06-17
ES2347428T3 (es) 2010-10-29
BR0007936B1 (pt) 2015-03-10
MXPA01007760A (es) 2003-06-24
ATE269341T1 (de) 2004-07-15
AU768574B2 (en) 2003-12-18
JP4698027B2 (ja) 2011-06-08
EP1147117A1 (de) 2001-10-24
FI120689B (fi) 2010-01-29
DE60011571D1 (de) 2004-07-22
CA2361582A1 (en) 2000-08-03
NO20013749L (no) 2001-09-25
ES2223464T3 (es) 2005-03-01

Similar Documents

Publication Publication Date Title
ATE269341T1 (de) Verbindungen mit immunologischem adjuvanseffekt
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
MXPA04002490A (es) Interleucina-12 como adyuvante de vacuna veterinaria.
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK1372708T3 (da) Vaccine til transkutan immunisering mod rejsediarre
ATE310008T1 (de) Immunologische adjuvans verbindungen
EP1395283A4 (de) Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine
DK1112747T3 (da) Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
WO1992006113A3 (en) Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
WO2002009749A3 (en) Respiratory syncytial virus vaccine
AU3478393A (en) Vaccine containing acemannan as an adjuvant
EA200800917A1 (ru) Адъюванты для вакцин
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
IL122829A (en) Isolated strains of staphylococcus aureus and vaccines manufactured therefrom
ATE431745T1 (de) Ltb4 als adjuvans für impfstoffe
WO2006109186A3 (en) Early endosome neutralising compouds as vaccine adjuvants
WO2003040163A3 (en) Immunomodulating saponins, a method for their preparation and their use for vaccines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties